Sensei Biotherapeutics (NASDAQ:FTH) Stock Price Down 5.3% – Here’s What Happened

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) fell 5.3% during trading on Friday . The stock traded as low as $37.26 and last traded at $36.9150. 157,405 shares changed hands during mid-day trading, a decline of 27% from the average daily volume of 216,524 shares. The stock had previously closed at $39.00.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Citizens Jmp began coverage on Sensei Biotherapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $51.00 target price on the stock. TD Cowen began coverage on Sensei Biotherapeutics in a report on Wednesday. They issued a “buy” rating for the company. Oppenheimer started coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price objective for the company. Finally, JonesTrading began coverage on shares of Sensei Biotherapeutics in a report on Tuesday, August 4th. They set a “buy” rating and a $55.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Sensei Biotherapeutics Trading Down 3.8%

The stock has a market cap of $969 million, a price-to-earnings ratio of -0.26 and a beta of -0.28. The firm has a fifty day moving average price of $31.05.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, beating the consensus estimate of ($5.04) by $2.20. As a group, sell-side analysts forecast that Sensei Biotherapeutics, Inc. will post -13.18 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Anand Kiran Parikh purchased 2,806 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the acquisition, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brian C. Stephenson acquired 9,391 shares of Sensei Biotherapeutics stock in a transaction on Wednesday, June 24th. The shares were bought at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the purchase, the chief financial officer owned 26,804 shares of the company’s stock, valued at $700,388.52. This represents a 53.93% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders bought 49,494 shares of company stock worth $1,188,822. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Sensei Biotherapeutics

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after buying an additional 1,100 shares during the period. Citadel Advisors LLC acquired a new stake in Sensei Biotherapeutics in the second quarter valued at approximately $307,000. Bank of America Corp DE grew its position in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Alyeska Investment Group L.P. purchased a new stake in shares of Sensei Biotherapeutics during the second quarter valued at approximately $3,610,000. Finally, Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics during the first quarter worth $4,188,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.